QLP-31907

N/A

Report date: 2025/07/26 20:00:09

Base Information

Drug NameQLP-31907
Drug Alias NameQLP-31907QLP31907PSB-202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD20Anti-Leukocyte antigen CD37
TargetsB-lymphocyte antigen CD20Leukocyte antigen CD37
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[7

Other Information

ATC CodeN/A
Related LinksN/A